Financial Daily
from THE HINDU group of publications
Friday, January 05, 2001
|
Financial Daily from THE HINDU group of publications Friday, January 05, 2001 |
||
|
|
||
|
• AGRI-BUSINESS • COMMODITIES • CORPORATE • INFO-TECH • LETTERS • LOGISTICS • MACRO ECONOMY • MARKETS • NEWS • OPINION • VARIETY • INFO-TECH • CATALYST • INVESTMENT WORLD • MONEY & BANKING • LOGISTICS |
Markets
| Next
| Prev
Alembic: Revenue pep, but...
THE permission received by Alembic to market a generic drug in the European Union countries may not lead to any immediate improvement in the valuation of the stock.
Alembic has secured the Certificate of Suitability for Roxithromycin whose patent expires this month in Germany and later in other countries. While the development may improve export and revenue base, the effect on profitability may take time to material
ise. In this context, in the near term, this development may not have any significant bearing on the stock price. -- BL Research Bureau
|
|
|
Comment on this article to BLFeedback@thehindu.co.in
Send this article to Friends by E-Mail
Next: Larsen & Toubro: More capacity, but... Prev: Tata Tea: Perking up? Markets Agri-Business | Commodities | Corporate | Info-Tech | Letters | Logistics | Macro Economy | Markets | News | Opinion | Variety | Info-Tech | Catalyst | Investment World | Money & Banking | Logistics | Copyrights © 2001 The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line. |